We measured plasma PFAS concentrations at baseline and during the second annual visit of the Diabetes Prevention Program (DPP) trial that has followed participants prospectively for approximately 15 years after randomization as part of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort. This evidence concerns the gene PFAS and diabetes mellitus.